Carl Zeiss Meditec

Reasonably good Q2, despite underlying challenges/risks

13/05/22 -"Despite the supply-chain challenges, CZM reported a reasonably good set of Q2 21/22 results. Both segments reported double-digit growth and order intake was impressive. Unlike most of the MedTech ..."

PDF page sample
Pages
63
Language
English
Published on
13/05/22
Download
You may also be interested by these reports :
05/11/25
Demant’s Q3 organic sales slightly exceeded expectations, driven by growth in hearing care and hearing aids, though partially offset by weakness in ...
05/11/25
Fresenius delivered strong Q3 results, driven by broad-based growth across Kabi and Helios, with improving margins despite some challenges. Kabi’s ...
05/11/25
Qiagen reported better-than-expected Q3 results, with healthy growth across segments supporting the top line. Profitability also improved, prompting ...
04/11/25
bioMerieux’s Q3 sales fell short of expectations. Organic sales growth was primarily driven by a robust performance in Industrial Applications. ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO